Review quantifies benefits, harms of mammography

Review quantifies benefits, harms of mammography
The benefits and harms of screening mammography have been quantified in a special communication published online Dec. 30 in JAMA Internal Medicine.

(HealthDay)—The benefits and harms of screening mammography have been quantified in a special communication published online Dec. 30 in JAMA Internal Medicine.

H. Gilbert Welch, M.D., M.P.H., and Honor J. Passow, Ph.D., from the Dartmouth Institute for Health Policy and Clinical Practice in Hanover, N.H., provide a range of estimates for the absolute frequency of breast cancer deaths avoided, false alarms, and overdiagnosis associated with screening mammography. Data were used from nine and are specific to the United States.

The researchers found that, among 1,000 U.S. women aged 50 years who underwent annual screening for 10 years, 0.3 to 3.2 will avoid a death; 490 to 670 will experience one or more false alarms; and overdiagnosis and needless treatment will affect three to 14.

"We hope that these data are sufficient for some women to make the decision about whether or not to be screened," the authors conclude. "Some may choose to pursue screening, valuing any potential for benefit as warranting the accompanying harms. Others may choose not to pursue screening, valuing the plausible range for the magnitude of the harms as being too great to justify pursuing the relatively small benefit."

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Informing women on breast cancer overdiagnosis

Jan 24, 2013

In a study exploring women's responses to being told about overdiagnosis in breast cancer screening, most women felt the information was important and could enable them to make choices.

Recommended for you

Scientists discover hidden subpopulation of melanoma cells

3 hours ago

UNC School of Medicine researchers have pinpointed a set of intriguing characteristics in a previously unknown subpopulation of melanoma cancer cells in blood vessels of tumors. These cells, which mimic non-cancerous ...

Blood biomarker may detect lung cancer

21 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

User comments